We’re pleased to share some new milestones across multiple clinical trials featuring our lead candidate EXL01.

Oncology:

- EXLIBRIS (NCT06448572): Recruitment for part 1 of the study is now complete at CHU de Lille. The trial evaluates the use of EXL01 as an advanced line treatment, in combination with nivolumab (anti-PD-L1), for patients who are refractory to this immunotherapy.

- MOTHER (NCT06551272): Recruitment has been completed for part 1 of this clinical trial in hepatocellular carcinoma, led by Centre Eugène Marquis of Rennes. By administering EXL01 in combination with immune checkpoint inhibitors (i.e., immunotherapies), the goal is to boost their efficacy and convert previously non-responsive patients into responders. Enrollment in part 2 of the trial has started

Inflammatory Disease - Crohn’s Disease

- MAINTAIN POP (NCT06925061): Recruitment is ongoing as planned since the launch in April. This is a Phase 2 randomized clinical trial evaluating EXL01 in postoperative Crohn’s disease patients, in collaboration with hashtag#REMIND and 14 French gastroenterology departments.

Infectious Disease – Infection to C. difficile:

- LIVEDIFF (NCT063060): Recruitment has resumed and the first patients have been enrolled in part two of the study. Supported by the French Ministry of Health and conducted in collaboration with Dr Nicolas Benech at Hospices Civils de Lyon - HCL, the trial aims to demonstrate EXL01's safety and efficacy in high-risk Clostridioides difficile infection (CDI) patients.

More information can be found on clinicaltrials.gov

‍